feb 12, 2019: 11 a.m. - middag
Shubert Complex - 6th Floor
The U.S. Department of Health and Human Services has proposed piloting an %u201CInternational Pricing Index%u201D (IPI) payment model to reduce reimbursement levels for the Centers for Medicare & Medicaid Services (CMS), as well as proposing other reforms to long-standing policies regarding commercialized medicines. In a year with a record number of new medicines being approved to reach patients in the United States, such reforms introduce significant uncertainty for many investors%u2019 valuation models. This session will feature drug developers, investors, and policy experts to explain the resource allocation implications if these reforms proceed and risks of shrinking the pipelines of new medicines for years to come unless alternative approaches can be introduced.
Moderator: James C. Greenwood, President and CEO, Biotechnology Innovation Organization (BIO)